SAN FRANCISCO, CA - FibroGen (NASDAQ:FGEN), Inc., a pharmaceutical company, has been notified by the Nasdaq Stock Market of non-compliance with the minimum bid price rule, as its common stock closed below $1.00 per share for 30 consecutive business days.
The company received the notification on September 12, 2024, which does not immediately affect its listing.
The company, traded under the ticker NASDAQ:FGEN, has until March 11, 2025, to regain compliance. During this 180-day grace period, FibroGen must maintain a closing bid price of at least $1.00 per share for at least ten consecutive business days. The company may be granted an additional 180 days to meet the requirements if necessary conditions are met.
FibroGen confirmed it currently satisfies all other Nasdaq initial listing standards except for the bid price. The company plans to actively monitor its stock's bid price and explore options to address the deficiency. This may include a reverse stock split if it becomes necessary to comply with Nasdaq's requirements.
The above news is based on an 8K filing.
In other recent news, FibroGen Inc . has announced significant changes to its executive team as part of ongoing cost reduction efforts. Chief Financial Officer Juan Graham and Chief Medical Officer Deyaa Adib have been given notice of termination, with their departures scheduled for December and November, respectively. This move is part of a broader strategy to streamline operations within the organization.
In recent developments, FibroGen experienced a mix of setbacks and progress in its second quarter of 2024. The company reported a significant disappointment with the failure of pamrevlumab in pancreatic cancer trials, leading to a substantial cost reduction plan which includes a 75% reduction in US headcount. Despite this, FibroGen also reported promising developments with its drug FG-3246 for metastatic castration-resistant prostate cancer and ongoing success with roxadustat in China.
The company raised its full-year 2024 guidance for net product revenue and roxadustat net sales in China, suggesting a strong financial position and potential for strategic partnerships. Total revenue for Q2 2024 was up 14% year-over-year, primarily driven by roxadustat sales in China, which increased by 21%. Despite a net loss of $15.5 million for Q2 2024, FibroGen expects to fund operations into 2026 with its current cash position.
InvestingPro Insights
As FibroGen faces challenges with Nasdaq's minimum bid price rule, a closer look at the company's financial health and market performance through InvestingPro data and tips reveals a nuanced picture. FibroGen's market capitalization currently stands at a modest $46.18 million, reflecting investor caution. Despite a significant 33.11% revenue growth over the last twelve months as of Q2 2024, the company grapples with weak gross profit margins of -34.4%, underlining operational difficulties. The stock has experienced volatility with a strong return over the last month of 28.59%, yet it has seen a steep price decline of 77.51% over the last six months, which may concern investors.
InvestingPro Tips indicate that FibroGen has a high shareholder yield but is quickly burning through cash, which could impact its ability to sustain operations without additional financing. Moreover, analysts do not anticipate the company will be profitable this year, and the valuation implies a poor free cash flow yield. These factors must be weighed by investors as they consider the company's strategies to regain Nasdaq compliance and its long-term viability.
For those seeking a deeper analysis, there are over 10 additional InvestingPro Tips available, offering insights that could help investors make more informed decisions about FibroGen's prospects. These tips, along with real-time metrics, can be accessed through InvestingPro's dedicated page for FibroGen at https://www.investing.com/pro/FGEN.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.